Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen

Indian Journal of Cancer

Volumn 46, Issue 4, 2009, Pages 311-317

  Arora, R ^a   Thakur, J S ^a   Azad, R K ^a   Mohindroo, N K ^a   Sharma, D R ^a   Seam, R K ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

Audiometry; Cisplatin; Hearing loss

Indexed keywords

CISPLATIN;

ADULT; ARTICLE; AUDIOMETRY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CARCINOMA; LOW DRUG DOSE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; OTOTOXICITY; PERCEPTION DEAFNESS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TESTIS CARCINOMA; TINNITUS; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TINNITUS; YOUNG ADULT;

EID: 70349422409     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.55551     Document Type: Article

References (35)

1. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004;40:2445-2451
2. Vantrappen G, Rector E, Debruyne F. The ototoxicity of cisplatin: A clinical study. Acta Otorhinolaryngol Belg 1990;44:415-421
3. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988:858-864
4. Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983;12:365-369
5. Domenech J, Cuchi MA, Carulla M. High-frequency hearing loss in patients with tinnitus. Adv Otorhinolaryngol 1990;45:203-205
6. Laurell G, Jungnelius U. High-dose cisplatin treatment: Hearing loss and plasma concentrations. Laryngoscope 1990;100:724-734
7. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994;15:232-239
8. Ozturan O, Jerger J, Lew H, Lynch GR. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx 1996;23:147-151
9. Coradini PP, Cigona L, Selitre SG, Resito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007;29:355-360
10. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001;59:47-57.
11. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol2005;23:8588-8596
12. Leary SO. Ototoxicty. In: Gleeson M, editor. Scott Browns Otorhinolaryngology, Head and Neck Surgery. Vol 3, 7th ed, Hodder Arnold. London: 2008. p. 3567-3573
13. Berg AL, Spitzer JB, Garvin JH Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 1999;109:1806-1814
14. Toral-Martinnon R, Collado-Corona MA, Mora-Magana I, Leal-Leal C, Gutierrez-Castrellon P, Gonzalez-de Leo S. Evaluation of cisplatin ototoxicity by the audiometric curve in retinoblastoma. Cir Cir 2006;74:79-82.
15. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649-655
16. Laurell G, Borg E. Ototoxicity of cisplatin in gynaecological cancer patients. Scand Audiol 1988;17:241-247
17. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, Bagby GC Jr. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993;119:661-666
18. Borges GC, Borges RH, Barauna GN, Lopes Filho O. Cisplatin Ototoxicity in Children: Retrospective study. Revista Brasileira de Otorrinolaringologia 2001;67:292-295
19. Schmidt CM, Knief A, Lagosch AK, Deuster D, Zehnhoff-Dinnesen A. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected. Ear Hear 2008;29:830-837
20. Hrushesky WJ. Circardian timing of cancer chemotherapy. Science 1985;228:73-75
21. Hecquet B, Meynadier J, Bonneterre J, Adenis L, Demaille A. Time dependency in plasmatic protein binding of cisplatin. Cancer Treat Rep 1985;69:79-83
22. Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983;19:53-58
23. Dutta A, Venkatesh MD, Kashyap RC. Study of the effect of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 2005;57:226-228
24. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007;72:931-935
25. Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 2008;29:1005-1011
26. Yassuda CC, Righetti AE, Cury MC, Hyppolito MA, de Oliveira JA, Feres O. The role of hyperbaric oxygen therapy (hot) as an otoprotection agent against cisplatin ototoxicity. Acta Cir Bras 2008;23:72-76
27. Huang X, Whitworth CA, Rybak LP. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol 2007;28:828-833
28. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21:513-520
29. Husain K, Whitworth C, Somani SM, Rybak LP. Partial protection by lipoic acid against carboplantin-induced ototoxicity in rats. Biomed Environ Sci 2005;18:198-206.
30. Whitworth CA, Ramkumar V, Jones B, Tsukasaki N, Rybak LP. Protection against cisplatin ototoxicity by adenosine agonists. Biochem Pharmacol 2004;67:1801-1807
31. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538-542
32. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, et al. Ototoxicity in a randomized phase III trial of intraarterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007;25:3759-3765
33. Tange RA, Dreschler WA, van der Hulst RJ. The importance of hightone audiometry in monitoring for ototoxicity Arch Otorhinolaryngol 1985;242:77-81.
34. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007;25:1190-1195
35. Biro K, Noszek L, Prekopp P, Nagyivanyi K, Geczi L, Gaudi I, et al. Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE). Magy Onkol 2007;50:329-335